Radius, 3M Drug Delivery Systems Announce Exclusive Agreement for Development, Commercialization of Transdermal Delivery of BA058 for Osteoporosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Radius Health, Inc. (“Radius”) and 3M Drug Delivery Systems are pleased to announce an exclusive partnership agreement for development and commercialization of BA058-transdermal (TD). BA058 is a novel, synthetic proprietary peptide analog of human parathyroid hormone related protein or “hPTHrP,” a bone building anabolic compound with the potential to treat patients with osteoporosis at high risk of fracture. This agreement updates the general development agreement announced in May 2011 by the two companies for BA058-TD. BA058-transdermal (TD) is being studied in a Phase 2 clinical trial in healthy postmenopausal women with osteoporosis at 10 clinical centers. BA058-TD is a short-wear time patch based on 3M’s patented Microstructured Transdermal System technology. The transdermal patch is expected to combine ease of use, convenience and self-administration attributes of a patch with the bone building efficacy of the BA058 compound.